HHLA2 and clear cell renal carcinoma: In addition, Zhou et al. demonstrated that the co-expression of HHLA2 and PD-L1 negatively impacted the prognosis of clear cell renal cell carcinoma patients, suggesting these patients may derive advantages from the combined inhibition of both PD-L1 and HHLA2 [26].